University of Southern California
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Southern California sits in the top decile of US sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count).
University of Southern California: 617 sponsored US clinical trials, 97 recruiting.
University of Southern California sponsors 617 registered US clinical trials on ClinicalTrials.gov, 97 of them currently recruiting, and 361 completed. 31 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
University of Southern California ranks in the top decile of sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
361 of 466 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
617 total, page 13 of 13
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00005841
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
NCT00183950
Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
NCT00006037
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
NCT00183859
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
NCT00184093
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00006113
IM-862 in Treating Patients With Recurrent Ovarian Cancer
NCT00003773
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003339
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT00003449
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
NCT00003274
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
NCT00003050
Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer
NCT00003085
Cryosurgery in Treating Patients With Soft Tissue Sarcoma
NCT00002863
Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer
NCT00003009
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
NCT00002955
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
NCT01953211
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients
NCT00002052
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 83 |
| Phase 2 | 90 |
| Phase 3 | 9 |
| Phase 4 | 22 |
Therapeutic Areas
What is open in the University of Southern California pipeline
97 recruiting of 617 indexed (16% open); 361 completed (59%).
Phase mix: 31 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Southern California: open-pipeline peers nationwide
Peers matched on 617 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 617 trials (± recruiting share)
- Baylor College of Medicine · 616 trials · 15% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Rochester · 636 trials · 15% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Youngstown State University · 16% recruiting · 19 trials
- Roswell Park Cancer Institute · 16% recruiting · 365 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- University of Oregon · 16% recruiting · 63 trials
Related
What to do with this University of Southern California page
617 registered trials is a research-attention snapshot, not an endorsement of University of Southern California or any single study.
- 97 of University of Southern California's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Southern California studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Southern California pipeline card: 617 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.